Writing
The recent approval of the Suzetrigin by the United States Food and Medicines Administration (FDA) represents a clinical advance of great relevance in the treatment of the consumer agudo posterquirric. This new drug, which will be marketed under the name of Journavxoffers one Effective alternative to opioid treatment, Without the risks associated with tolerance, dependence or withdrawal syndrome.
Ana María MartínDoctor of Pharmacy and professor at the Faculty of Biomedical and Health Sciences of the European University, stressed that suzetrigine represents a “Great advance” both in the treatment of acute pain in adults and in the fight against The crisis of dependence on opioidsa growing international problem, according to Europa Press.
Suzetrigin acts by a innovative and highly specific mechanism of actionthat clearly differentiates it from traditional analgesics. Specifically, Selectively block the sodium channel activated by Voltage Nav 1.8directly involved in the transmission of pain signals from the peripheral nerves to the central nervous system.
Suzetrigine represents a “great advance” both in the treatment of acute pain in adults and in the fight against the crisis of dependence on opioids
“The main difference between suzetrigine and opioids lies in its mechanism of action,” Dr. Martín explained. «This drug inhibits the Nav 1.8 channel, which is key in the transmission of the painful signal through the C and Delta fibers. It is just at this point where it manages to stop pain spread to avoid its amplification », The expert has pointed out.
Unlike opioids, which They cross the blood brain barrier And they are widely distributed by the central nervous system due to its high liposolubility, suzetrigin has a more localized profile. This characteristic minimizes side effects at brain level and eliminates addiction riskone of the main concerns in the prolonged use of opioids.
For now, Suzetrigine is indicated exclusively for the treatment of postoperative acute painalthough the responsible laboratory has announced ongoing studies to explore its application in other types of pain, including Chronic neuropathic painone of the most challenging areas in the field of analgesia.
For now, suzetrigine is indicated exclusively for the treatment of postoperative acute pain
His arrival at the European market still has no date. Although the pharmaceutical company has a presence in Europe with other products, such as cystic fibrosis treatments, Dr. Martín has warned that it is still early to anticipate its availability in Spain. «We will have to wait for El Comité de Medicamentos de Uso Humano (CHMP) From the European Medication Agency publishes its calendar to know the pending regulatory steps », He has stressed.
Thus, the approval of Suzetrigin marks a milestone within the search for non -opioid alternatives for pain management. In a sanitary context where the adverse effects of opioids have reached proportions of crisis, The introduction of an effective and non -addictive drug such as suzetrigine is a strategic advance in medical practice.
Health professionals must now closely follow follow -up studies, future clinical guides and regulatory evolution in Europe, in order to assess their incorporation into the usual pharmacotherapy in the treatment of postoperative pain and other forms of pain in need of safe and effective approach.
Related news :